Luye Pharma Group Ltd.

SZSC:2186 Stock Report

Market Cap: HK$8.0b

Luye Pharma Group Past Earnings Performance

Past criteria checks 4/6

Luye Pharma Group's earnings have been declining at an average annual rate of -27.5%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been declining at an average rate of 0.03% per year. Luye Pharma Group's return on equity is 5.9%, and it has net margins of 12.2%.

Key information

-27.5%

Earnings growth rate

-31.5%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate-0.03%
Return on equity5.9%
Net Margin12.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Luye Pharma Group makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSC:2186 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 246,3147702,4280
31 Mar 246,2286522,5640
31 Dec 236,1435332,7000
30 Sep 236,0894952,7050
30 Jun 236,0354582,7110
31 Mar 236,0085312,5570
31 Dec 225,9826052,4030
30 Sep 225,5411902,3650
30 Jun 225,099-2242,3270
31 Mar 225,150-1792,3010
31 Dec 215,200-1342,2760
30 Sep 215,3652102,1960
30 Jun 215,5295542,1160
31 Mar 215,5346302,1510
31 Dec 205,5407072,1850
30 Sep 205,8649552,3020
30 Jun 206,1891,2042,4190
31 Mar 206,2731,3002,4910
31 Dec 196,3581,3962,5640
30 Sep 196,2291,4342,5060
30 Jun 196,1011,4722,4480
31 Mar 195,6371,3882,2870
31 Dec 185,1731,3032,1270
30 Sep 184,6711,2311,9570
30 Jun 184,1681,1591,7870
31 Mar 183,9911,0701,7530
31 Dec 173,8159811,7180
30 Sep 173,5479171,6290
30 Jun 173,2808521,5390
31 Mar 173,0998721,4640
31 Dec 162,9188921,3890
30 Sep 162,7848431,3100
30 Jun 162,6497941,2320
31 Mar 162,6067741,1900
31 Dec 152,5637551,1490
30 Sep 152,4817321,0370
30 Jun 152,4007109240
31 Mar 152,4726581,0460
31 Dec 142,5446061,1680
30 Sep 142,7055341,4150
30 Jun 142,8664621,6610
31 Mar 142,6903861,5930
31 Dec 132,5153101,5250

Quality Earnings: 2186 has high quality earnings.

Growing Profit Margin: 2186's current net profit margins (12.2%) are higher than last year (7.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 2186's earnings have declined by 27.5% per year over the past 5 years.

Accelerating Growth: 2186's earnings growth over the past year (68.3%) exceeds its 5-year average (-27.5% per year).

Earnings vs Industry: 2186 earnings growth over the past year (68.3%) exceeded the Pharmaceuticals industry 9.4%.

Return on Equity

High ROE: 2186's Return on Equity (5.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Luye Pharma Group Ltd. is covered by 25 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Wai Chak YuenBOCI Research Ltd.
Bo LiBOCOM International Securities Limited